GlassScriptPhysician profile
Calem Al-Shaikhly
NPI 1114570090
$3,767.54
in general payments reported to CMS, 2019-2025
32 companies · $1,500 in 2025
The $1,500 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $143 · 2020: $13.39 · 2022: $140 · 2023: $927 · 2024: $1,044 · 2025: $1,500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,345 · Education: $126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,345.43 |
| Education | $125.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $453.35 | 2019-2025 | Vraylar, Ubrelvy |
| Novo Nordisk INC | $414.85 | 2022-2025 | Ozempic, Rybelsus, Tresiba |
| Astellas Pharma US INC | $384.98 | 2023-2025 | Veozah, Myrbetriq |
| Lilly USA, LLC | $323.09 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $225.42 | 2022-2025 | |
| Inari Medical, INC. | $215.50 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Medtronic, INC. | $166.12 | 2023-2024 | O-Arm, Intellis Adaptivestim, Venaseal |
| Exact Sciences Corporation | $152.67 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Dexcom, INC. | $146.53 | 2022-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $141.04 | 2019-2024 | Capvaxive, Gardasil 9, Vaxelis |
| Amgen INC. | $134.89 | 2022-2025 | Krystexxa, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.27 | 2024-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $108.34 | 2023-2025 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $102.80 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $85.11 | 2024-2025 | Shingrix, Arexvy, Trelegy Ellipta |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $75.62 | 2024-2025 | Airsupra |
| Janssen Pharmaceuticals, INC | $62.55 | 2022-2023 | Spravato |
| Antares Pharma, INC. | $55.28 | 2023-2025 | Xyosted, Tlando, Nocdurna |
| Eisai INC. | $49.92 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.58 | 2024-2025 | |
| Ascensia Diabetes Care US INC. | $41.90 | 2023-2025 | |
| Abbott Laboratories | $40.89 | 2024-2025 | Freestyle Libre 3, Proclaim |
| Edwards Lifesciences Corporation | $39.17 | 2023-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Ani Pharmaceuticals, INC. | $31.50 | 2024 | Purified Cortrophin Gel |
| Esperion Therapeutics, INC. | $29.16 | 2024 | Nexletol |
| Dynavax Technologies Corporation | $19.95 | 2025 | Heplisav-B |
| Biohaven Pharmaceutical Holding Company LTD. | $18.85 | 2022 | |
| Axsome Therapeutics, INC. | $18.09 | 2025 | Symbravo |
| Corcept Therapeutics | $15.46 | 2025 | Korlym |
| Currax Pharmaceuticals LLC | $14.18 | 2025 | Contrave |
| Halozyme INC | $14.09 | 2023 | |
| Janssen Biotech, INC. | $13.39 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Calem Al-Shaikhly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.